From Warsaw, a Femtech Star Rises: MY OVU's Path to CES 2027

WARSAW, Poland – June 22, 2026 – In a significant validation of European innovation, the Consumer Technology Association (CTA)® has crowned Polish startup MY OVU the winner of its prestigious pitch competition at the CEO Summit held here in Warsaw. The victory secures the company a complimentary exhibit space in Eureka Park—the dedicated startup arena at CES® 2027 in Las Vegas—placing its groundbreaking women's health technology on the world's most influential stage.

The win is more than just a ticket to Vegas; it's a powerful endorsement of a burgeoning Polish tech ecosystem and a strategic leap forward for a company poised to disrupt the multi-billion dollar Femtech market. MY OVU was selected from a competitive field of five Polish startups by a panel of discerning investors, underscoring the strength and viability of its vision.

"Winning the pitch competition at CTA CEO Summit is a significant milestone for our team," said Aleksandra Staniszewska, CEO & Founder of MY OVU. "The opportunity to present our technology to global business leaders and exhibit at CES 2027 will help us expand our international visibility and accelerate the next phase of our growth."

A New Standard in Women's Health Technology

At the heart of MY OVU's victory is its flagship product: a medical-grade intelligent ovulation thermometer. This isn't another generalized wellness wearable or statistical prediction app. The company has engineered a highly specialized device designed to provide clinical-level accuracy in the comfort of one's home. The system uses a flexible, medical-grade silicone vaginal ring that measures deep body temperature overnight. This method bypasses the inaccuracies inherent in measuring skin temperature, which can be influenced by ambient room temperature, blankets, or restless sleep.

By continuously gathering basal body temperature (BBT) data with a precision of 0.01°C, the device provides a far more reliable dataset for its AI-powered algorithms. The AI analyzes these subtle thermal shifts to pinpoint a user's fertile window with remarkable accuracy, identify ovulation, and even detect hormonal irregularities that could signal underlying health issues or the onset of perimenopause. For women trying to conceive, this precision can dramatically shorten the time to pregnancy by eliminating guesswork. For those navigating the complexities of perimenopause, where cycles become erratic, the device offers clarity in a time of uncertainty.

The technology directly addresses a critical gap in the Femtech market, which has long been dominated by solutions that prioritize convenience over accuracy. MY OVU's patented system eliminates the daily chore of manual temperature taking upon waking, as the device works automatically during sleep. The data is seamlessly synced to a mobile app that provides not just raw numbers, but actionable insights and personalized predictions, empowering women with a deeper understanding of their own bodies.

The Rise of Polish and European Innovation

MY OVU's success is a potent symbol of the maturation of Poland's technology sector. The nation is rapidly shedding its reputation as merely an outsourcing hub and emerging as a source of deep-tech innovation, particularly in specialized fields like Medtech and Femtech. The CTA's decision to host its CEO Summit in Warsaw was a deliberate nod to this growing influence.

"Poland's startup ecosystem produces bold entrepreneurs developing technologies with global potential," noted Kinsey Fabrizio, President and CEO of CTA. She highlighted that the Polish Agency for Enterprise Development (PARP) had already supported a national presence at CES 2026, signaling a coordinated effort to promote the country's innovators abroad. "We are thrilled to welcome MY OVU to CES 2027 – where what's next is on display now."

The judging panel for the competition, comprising Zuzanna Kompowska of Inovo VC, Kris Palucki of OTB Ventures, and Paulina Brym-Ciuba of StartupHub Poland, represents the robust domestic venture capital and support infrastructure that is fueling this growth. Their evaluation, based on innovation, business strategy, and market potential, confirms that MY OVU is not just a compelling idea but a viable business ready for the international market.

The Eureka Park Launchpad: A Gateway to Global Scale

For a startup like MY OVU, a spot in Eureka Park at CES is transformative. This curated space is the epicenter of breakthrough innovation at the show, drawing a concentrated audience of investors, corporate partners, and global media searching for the next big thing. It's a crucible where a well-prepared startup can secure a seed round, sign a pivotal distribution deal, or gain the media exposure that catapults it from obscurity to a recognized brand—all in the span of four days.

Exhibiting at CES provides an unparalleled platform for validation. It allows MY OVU to move beyond pitching a concept and instead demonstrate a market-ready product to a global audience. The connections made in Las Vegas can accelerate a company's growth trajectory by years, opening doors to international markets and strategic collaborations that would be difficult to secure otherwise. As Staniszewska noted, the win is a direct catalyst for accelerating the company's next phase of growth, a sentiment echoed by countless Eureka Park alumni who point to the event as a critical inflection point in their journey.

Redefining the Femtech Market

MY OVU enters a dynamic and rapidly expanding Femtech market, but with a clear and defensible differentiator. While competitors offer solutions ranging from hormone-tracking urine tests to wrist-worn temperature sensors, MY OVU's focus on high-precision, internal body temperature measurement addresses a core need for accuracy and reliability. The company's B2C launch in Poland is just the beginning, with a strategic roadmap that includes B2B partnerships with other health apps and insurers, and even B2G public health initiatives.

This victory in Warsaw is more than a single company's triumph; it is a clear signal of several converging trends. It showcases the rise of targeted, science-backed solutions in women's health, the increasing global competitiveness of Central and Eastern European tech hubs, and the enduring power of global platforms like CES to launch the innovations that will define our future.